Comparison of different positron emission tomography tracers in patients with recurrent medullary thyroid carcinoma: our experience and a review of the literature.

Several morphological and functional imaging techniques are usually used to detect residual/recurrent medullary thyroid carcinoma (MTC) with variable results; currently, there is growing interest in positron emission tomography (PET) methodology. Herein, we report our experience of and a literature review about the comparison of different positron emission tomography (PET) tracers in patients with residual/recurrent MTC. (18)F-DOPA PET/CT seems to be the most useful imaging method to detect recurrent MTC lesions, performing better than (18)F-FDG and (68)Ga-somatostatin analogs PET/CT. (18)F-FDG may complement (18)F-DOPA in patients with aggressive tumors. (68)Ga-somatostatin analogs PET/CT may be useful to select patients who could benefit from radioreceptor therapy. The information provided by the various PET tracers reflects different metabolic pathways, and may help to select the most appropriate treatment.

[1]  E. Nitzsche,et al.  18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels , 2001, European Journal of Nuclear Medicine.

[2]  J. Sygut,et al.  The role of PET-CT scan with somatostatin analogue labelled with gallium-68 (⁶⁸Ga-DOTA-TATE PET-CT) in diagnosing patients with disseminated medullary thyroid carcinoma (MTC). , 2010, Endokrynologia Polska.

[3]  N. Wieshmann,et al.  Imaging of neuroendocrine tumours , 2010, Regulatory Peptides.

[4]  Richard P Baum,et al.  Imaging of neuroendocrine tumors. , 2006, Seminars in nuclear medicine.

[5]  P. Castaldi,et al.  Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma , 2011, Nuclear medicine communications.

[6]  B. Beuthien-Baumann,et al.  Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  E. D. de Vries,et al.  18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation , 2008, Journal of Nuclear Medicine.

[8]  H. Dralle,et al.  The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT , 2009, European Radiology.

[9]  M. Cremonesi,et al.  Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues: ten years experience , 2008 .

[10]  F. Raue.  Therapie des medullären Schilddrüsenkarzinoms , 1985 .

[11]  M. Papotti,et al.  Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid , 2001, Clinical endocrinology.

[12]  G. Treglia,et al.  Clinical significance of incidental focal colorectal 18F‐fluorodeoxyglucose uptake: our experience and a review of the literature , 2012, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

[13]  V. Ambrosini,et al.  68Ga-somatostatin analogues PET and 18F-DOPA PET in medullary thyroid carcinoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  Q. Duh,et al.  Medullary thyroid carcinoma , 2000, Cancer.

[15]  M. Schlumberger,et al.  Medullary thyroid carcinoma. , 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  B. Franc,et al.  Somatostatin receptors and somatostatin content in medullary thyroid carcinomas. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[17]  A. Toniato,et al.  Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[18]  A. Alavi,et al.  Nuclear medicine procedures in the diagnosis of NET: a historical perspective. , 2014, PET clinics.

[19]  J. Choi,et al.  Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT. , 2010, Endocrine journal.

[20]  I. Kayani,et al.  Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  V. Ambrosini,et al.  Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT , 2011, The Journal of Nuclear Medicine.

[22]  D. Rubello,et al.  Role of PET in medullary thyroid carcinoma. , 2008, Minerva endocrinologica.

[23]  P. Castaldi,et al.  Nuclear medicine procedures in the diagnosis and therapy of medullary thyroid carcinoma. , 2008, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[24]  E. Baudin,et al.  Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging , 2003, British Journal of Cancer.

[25]  D. Salvo,et al.  Ga-68 DOTATOC PET, Endoscopic Ultrasonography, and Multidetector CT in the Diagnosis of Duodenopancreatic Neuroendocrine Tumors: A Single-Centre Retrospective Study , 2010, Clinical nuclear medicine.

[26]  K. Usadel,et al.  Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. , 1998, Nuclear medicine communications.